Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8826605 | 1.00 | LTB4R (0.59) | LTB4RTSHRGRIK1KMT2ACYP2D6 | |
| SCHEMBL15587062 | 1.00 | LTB4R (0.59) | LTB4RTSHRGRIK1KMT2ACYP2D6 | |
| SCHEMBL7385392 | 0.94 | LTB4R (0.66) | LTB4RTSHRGRIK1KMT2ACYP2D6 | |
| SCHEMBL6344592 | 0.93 | LTB4R (0.68) | LTB4RTSHRKMT2ACYP2D6CYP2C9 | |
| SCHEMBL17027837 | 0.93 | LTB4R (0.68) | LTB4RTSHRKMT2ACYP2D6CYP2C9 | |
| SCHEMBL6971015 | 0.93 | LTB4R (0.68) | LTB4RTSHRKMT2ACYP2D6CYP2C9 | |
| SCHEMBL17027841 | 0.93 | LTB4R (0.68) | LTB4RTSHRKMT2ACYP2D6CYP2C9 | |
| SCHEMBL18019606 | 0.90 | FDFT1 (0.54) | LTB4RHDAC2 | |
| SCHEMBL27800230 | 0.90 | FDFT1 (0.54) | LTB4RHDAC2 | |
| SCHEMBL1073143 | 0.88 | TSHR (0.68) | LTB4RTSHRKMT2ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234643-B1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | ETH ZUERICH (CH) | 2013-01-09 | — | — | EP | claimed |
| EP-1967080-B1 | Non-aldehyde cinnamon flavor and delivery systems therefor | CADBURY ADAMS USA LLC (US) | 2010-06-02 | — | — | EP | claimed |
| CN-118434765-A | BCMA monoclonal antibodies and antibody-drug conjugates | 杭州多禧生物科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20240247030-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | JPMORGAN CHASE BANK, N.A. | 2024-07-25 | — | — | US | disclosed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| CN-114732916-B | Targeted delivery of tertiary amine-containing drug substances | 西雅图基因公司 | 2023-12-19 | — | — | CN | disclosed |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116143678-A | Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER | 2009-10-29 | — | — | US | disclosed |
| US-7572801-B2 | Pyridopyrimidinone derivatives which are HM74A agonists | HOFFMANN-LA ROCHE INC. (US) | 2009-08-11 | — | — | US | disclosed |
| CN-101448836-A | Pyridopyrimidinone derivatives | HOFFMANN LA ROCHE (CH) | 2009-06-03 | — | — | CN | disclosed |
| EP-2029601-A1 | PYRIDOPYRIMIDINONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| US-20070275987-A1 | Novel pyridopyprimidinone derivatives which are HM74A agonists | HOFFMAN-LA ROCHE INC | 2007-11-29 | — | — | US | disclosed |
| WO-2007134986-A1 | PYRIDOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20040006141-A1 | Amidocarboxylic acid compounds | SANKYO COMPANY, LTD (JP) | 2004-01-08 | — | — | US | disclosed |
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240247030-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | CD47, CD44, MSR1 | LTB4R 465/4885TSHR 802/4885GRIK1 1296/4885 |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | LTB4R 10/4885TSHR 554/4885GRIK1 657/4885 |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | LTB4R 852/4885TSHR 881/4885GRIK1 2085/4885 |
| US-20040006141-A1 | Amidocarboxylic acid compounds | NR1H2, AGK, APOL1 | LTB4R 885/4885TSHR 257/4885GRIK1 596/4885 |
| US-20070275987-A1 | Novel pyridopyprimidinone derivatives which are HM74A agonists | GPR119, HCAR1, GPR84 | LTB4R 116/4885TSHR 458/4885GRIK1 2282/4885 |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | LTB4R 2227/4885TSHR 1886/4885GRIK1 1823/4885 |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | LTB4R 10/4885TSHR 554/4885GRIK1 657/4885 |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | LTB4R 2227/4885TSHR 1886/4885GRIK1 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.